title: Correlating patient-reported response to hydroxypropyl cellulose ophthalmic insert (LACRISERT®) therapy with clinical outcomes: tools for predicting response.
abstract: OBJECTIVE
  To determine whether patient-reported improvement in symptoms of dry eye syndrome, activities of daily living, and other quality-of-life measures after treatment with hydroxypropyl cellulose ophthalmic inserts correlates significantly with physician assessment of clinical outcomes.
  
  
  METHODS
  Patient registry of those treated for 1 month with inserts as monotherapy or in combination with existing treatments for moderate-to-severe dry eye syndrome. A total of 520 participants were enrolled. Of those, 418 patients completed the study. Results of this registry were evaluated and correlations were calculated to determine whether patient-reported symptoms, quality of life, and changes in disease severity based on the Ocular Surface Disease Index, and activities of daily living outcomes are predictive of physician assessment of clinical signs, symptoms, and adherence to therapy.
  
  
  RESULTS
  Most patients reported overall improvement in their condition. Patient-reported improvements in the symptoms of dry eye syndrome and activities of daily living were significant predictors of physician assessment of compliance with insert therapy, improvement in symptoms and clinical signs, effectiveness of therapy, and acceptance of use as adjunctive therapy.
  
  
  CONCLUSIONS
  Patient-reported symptoms and activities of daily living are predictors of patient compliance and treatment success with the use of inserts, as reported by treating physicians. The benefits were additive to the standard of care that was continued during the course of the study. These predictors, along with clinical diagnostic tests, can be used by eye care professionals to assess the efficacy of treatment for moderate-to-severe dry eye syndrome quickly and reliably.
authors.affiliation: Ophthalmic Consultants of Long Island, 360 Merrick Road, Lynbrook, NY 11563, USA. margueritemcdmd@aol.com
authors.forename: Marguerite
authors.initials: M
authors.lastname: McDonald
authors.forename: Gerard
authors.initials: G
authors.lastname: D'Aversa
authors.forename: Henry D
authors.initials: HD
authors.lastname: Perry
authors.forename: John R
authors.initials: JR
authors.lastname: Wittpenn
authors.forename: Donald S
authors.initials: DS
authors.lastname: Nelinson
mesh_terms: D002482:Cellulose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000592:standards; D016503:Drug Delivery Systems / Q000379:methods / Q000592:standards; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010361:Patients / Q000523:psychology*; D010820:Physicians / Q000523:psychology*; D011379:Prognosis; D011788:Quality of Life; D012042:Registries; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002482:Cellulose; C008079:hydroxypropylcellulose